1. Gedeborg R, Styrke J, Loeb S, Garmo H, Stattin P. Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic. PLoS One. 2021 Oct. Sammanfattning. Fulltext.
  2. Fallara G, Alverbratt C, Garmo H, Vikman H, Hjelm Eriksson M, Lissbrant IF, Stattin P. Time on treatment with abiraterone and enzalutamide in the Patient-overview Prostate Cancer in The National Prostate Cancer Register of Sweden. Acta Oncol. 2021 Sep. Sammanfattning
  3. Godtman RA, Persson E, Cazzaniga W, Sandin F, Carlsson S, Ahlgren G, Johansson E, Robinsson D, Hugosson J, Stattin P. Association of surgeon and hospital volume with short-term outcomes after robot-assisted radical prostatectomy: Nationwide, population-based study. PLoS One. 2021 Jun. Sammanfattning.
  4. Bergengren O, Westerberg M, Holmberg L, Stattin P, Bill-Axelson A, Garmo H. Variation in Prostate-Specific Antigen Testing Rates and Prostate Cancer Treatments and Outcomes in a National 20-Year Cohort. JAMA Netw Open. 2021 May. Sammanfattning.
  5. Fallara G, Gedeborg R, Bill-Axelson A, Garmo H, Stattin P. A drug comorbidity index to predict mortality in men with castration resistant prostate cancer. PLoS One. 2021 Jul. Sammanfattning.
  6. Björklund J, Stattin P, Rönmark E, Aly M, Akre O. 90-day cause-specific mortality after radical prostatectomy. Nationwide population-based study. BJU Int. 2021 Jun. Sammanfattning 
  7. Shore R, Yu J, Ye W, Lagergren J, Rutegård M, Akre O, Stattin P, Lindblad M. Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer. Sci Rep. 2021 Jun. Sammanfattning
  8. Orrason AW, Garmo H, Styrke J, Dickman PW, Stattin P. Comparison of Relative Survival and Cause-specific Survival in Men with Prostate Cancer According to Age and Risk Category. Nationwide, Population-based Study. Am J Epidemiol. 2021 May. Sammanfattning
  9. Gedeborg R, Sund M, Lambe M, Plym A, Fredriksson I, Syrjä J, Holmberg L, Robinson D, Stattin P, Garmo H. An Aggregated Comorbidity Measure Based on History of Filled Drug Prescriptions: Development and Evaluation in Two Separate Cohorts. Epidemiology. 2021 Jul. Sammanfattning
  10. Lundström KJ, Garmo H, Gedeborg R, Stattin P, Styrke J. Short-term ciprofloxacin prophylaxis for prostate biopsy and risk of aortic aneurysm. Nationwide, population-based cohort study. Scand J Urol. 2021 Jun. Sammanfattning
  11. Fallara G, Sandin F, Styrke J, Carlsson S, Lissbrant IF, Ahlgren J, Bratt O, Lambe M, Stattin P. Prostate cancer diagnosis, staging, and treatment in Sweden during the first phase of the COVID-19 pandemic. Scand J Urol. 2021 Jun. Sammanfattning
  12. George G, Vikman H, Gedeborg R, Lissbrant IF, Garmo H, Styrke J, Van Hemelrijck M, Stattin P. Risk of cardiovascular events in men on abiraterone or enzalutamide combined with GnRH agonists: nation-wide, population-based cohort study in Sweden. Acta Oncol. 2021 Feb. Sammanfattning.
  13. Svensson J, Lissbrant IF, Gauffin O, Hjälm-Eriksson M, Kilany S, Fagerlund K, Stattin P. Time spent in hormone-sensitive and castration-resistant disease states in men with advanced prostate cancer, and its health economic impact: registry-based study in Sweden. Scand J Urol. 2021 Feb. Sammanfattning.
  14. Westerberg M, Larsson R, Holmberg L, Stattin P, Garmo H. Simulation model of disease incidence driven by diagnostic activity. Stat Med. 2021 Feb. Sammanfattning.
  15. Fallara G, Lissbrant IF, Styrke J, Montorsi F, Gedeborg R, Sandin F, Stattin P. Rapid ascertainment of uptake of a new indication for abiraterone by use of three nationwide health care registries in Sweden. Acta Oncol. 2021 Jan.  Sammanfattning.